JAMA Oncol: Trends in mortality and life expectancy of patients receiving allogeneic blood or bone marrow transplantation in the past 40 years

In the past 40 years, the practice of allogeneic blood or bone marrow transplantation (BMT) has undergone major changes.
The overall goal is to expand the eligible patient population while improving disease-free survival
.

This study aims to clarify the trends in life expectancy and cause-specific late mortality of patients undergoing allogeneic BMT in the past 40 years
.

This is a retrospective cohort study that included 4741 patients who survived ≥ 2 years after undergoing allogeneic BMT between January 1, 1974 and December 31, 2014
.

The last follow-up date is March 23, 2020

The overall survival rate of patients grouped according to the age of transplantation

The overall survival rate of patients grouped according to the age of transplantation

Of these 4741 patients, 2735 (57.
7%) were men, and the median age at the time of BMT was 33 years (range 0-75 years)
.

The cumulative recurrence-related mortality at 10 years after BMT stabilized, reaching 12.

The cumulative recurrence-related mortality at 10 years after BMT has stabilized, reaching 12.

Cumulative mortality

Cumulative mortality

Compared with 1974-1989, the adjusted 10-year all-cause mortality risk ratio (HR) decreased in three eras (1990-2004: HR 0.
67; 2005-2014: HR 0.
52; p<0.
001), life expectancy The same is true for shortened events (1974-1989: 9.
9 years; 1990-2004: 6.
5 years; 2005-2014: 4.
2 years)
.

The reduction in the late-stage mortality of patients who received transplantation before the age of 18 was the most obvious (compared with 1974-1989, 1990-2004: HR 0.

Reduce late mortality in patients receiving transplants before the age of 18 is most evident in the reduced late mortality in patients receiving transplants before the age of 18 in the most significant late mortality in patients undergoing bone marrow transplantation will be significantly lower in patients receiving bone marrow transplants The late mortality rate will also be significantly reduced

The cohort study pointed out that in the past 40 years, the late mortality of allogeneic BMT recipients has declined; however, life expectancy has not returned to the average level
.

In addition, the reduction in the risk of late death appears to be limited to those who received transplants or bone marrow transplants at a younger age

In the past 40 years, the late mortality rate of allogeneic BMT recipients has decreased; however, life expectancy has not returned to the level of ordinary people.

Original source:

Bhatia S, Dai C, Landier W, et al.

Mortality and Life in Late Trends Expectancy or the After Allogeneic Marrow Transplantation Over Blood of Decades.
4: A Blood Marrow Transplant Survivor or the Report Study JAMA in this message